Demographic and industry trends are widening the eye care gap and creating a practice growth opportunity for optometrists. As Americans age, demand rises for ocular surface disease (OSD) and other age-associated conditions — in 2025, the Dry Eye Syndrome treatment market hit $6.7 billion and is projected to grow to $11.1 billion by 2033. Additionally, the ophthalmology workforce is projected to decrease. This positions independent eye care professionals to expand medically necessary ocular surface services that improve clinical outcomes and support sustainable practice growth.
PECAA is working with industry partners to help optometrists expand medical optometry services, including in-office amniotic membrane therapy. The PECAA K-DISK dehydrated amniotic membrane is a convenient and easy to handle OSD and corneal healing treatment option that can be placed under a Collagen Shield or Bandage Contact Lens, providing a shelf-stable solution alongside BioTissue’s longstanding cryopreserved Prokera.